Nektar Therapeutics Announces Positive Phase 2b Trial Results

The latest announcement is out from Nektar Therapeutics ( (NKTR) ).

On June 24, 2025, Nektar Therapeutics announced the successful results of its Phase 2b REZOLVE-AD clinical trial for rezpegaldesleukin, a treatment for moderate-to-severe atopic dermatitis. The trial, involving 393 patients, showed statistically significant improvements in the primary and key secondary endpoints, including Eczema Area and Severity Score (EASI) and Itch Numerical Rating Score (NRS), across all dosage arms compared to placebo. The treatment demonstrated a robust dose-dependent reduction in inflammatory biomarkers and maintained a consistent safety profile with no increased risk of serious adverse events. These results highlight the potential of rezpegaldesleukin as a first-in-class immune-modulator for dermatological diseases, with further data expected in early 2026.

The most recent analyst rating on (NKTR) stock is a Buy with a $105.00 price target. To see the full list of analyst forecasts on Nektar Therapeutics stock, see the NKTR Stock Forecast page.

Spark’s Take on NKTR Stock

According to Spark, TipRanks’ AI Analyst, NKTR is a Neutral.

Nektar Therapeutics’ overall stock score is driven by its challenging financial performance, with persistent losses and high leverage. While the earnings call provided some positive insights into their pipeline advancements and cash position, the technical analysis and valuation metrics remain concerning, indicating financial instability and market uncertainty.

To see Spark’s full report on NKTR stock, click here.

More about Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing novel immunology therapies.

Average Trading Volume: 238,784

Technical Sentiment Signal: Strong Sell

Current Market Cap: $105.6M

For an in-depth examination of NKTR stock, go to TipRanks’ Overview page.